Spots Global Cancer Trial Database for epoch
Every month we try and update this database with for epoch cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | NCT01760226 | Diffuse Large B... Post Transplant... Primary Mediast... | DA-EPOCH-R for ... Methotrexate Etoposide Doxorubicin Vincristine Rituximab Cyclophosphamid... Prednisone G-CSF | - 30 Years | Baylor College of Medicine | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas | NCT00069238 | Lymphoma, T-Cel... Lymphoma, Extra... | Alemtuzumab (Ca... EPOCH | 17 Years - | National Institutes of Health Clinical Center (CC) | |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | NCT00114738 | Lymphoma, Mantl... Mantle Cell Lym... | Rituximab (R) EPOCH Bortezomib (B) Bortezomib Bortezomib or o... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas | NCT00069238 | Lymphoma, T-Cel... Lymphoma, Extra... | Alemtuzumab (Ca... EPOCH | 17 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | NCT01030900 | Hodgkin Lymphom... Diffuse Large B... | Campath Rituximab EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas | NCT00069238 | Lymphoma, T-Cel... Lymphoma, Extra... | Alemtuzumab (Ca... EPOCH | 17 Years - | National Institutes of Health Clinical Center (CC) | |
| EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | NCT00114738 | Lymphoma, Mantl... Mantle Cell Lym... | Rituximab (R) EPOCH Bortezomib (B) Bortezomib Bortezomib or o... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | NCT00006436 | Lymphoma, AIDS-... Lymphoma, Large... | Rituximab Filgrastim EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | NCT03586999 | Peripheral T Ce... | Nivolumab Etoposide Prednisolone Oncovin Cyclophosphamid... Hydroxydaunorub... | 18 Years - 80 Years | University of Colorado, Denver | |
| EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection | NCT00006436 | Lymphoma, AIDS-... Lymphoma, Large... | Rituximab Filgrastim EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma | NCT00001337 | Diffuse Large B... Primary Mediast... Burkitt Lymphom... Anaplastic Larg... Gray Zone Lymph... | EPOCH Rituximab | 12 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
